Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
- Written by PR Newswire Asia - News Pronto RSS
SUZHOU, China, Sept. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European Society for Medical Oncology Congress (ESMO Congress 2024) from September 13 to 17, 2024, in Barcelona,...

